Literature DB >> 11372733

Acute myelogenous leukemia with PIG-A gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome.

H Tanaka1, N Imamura, N Oguma, T Shintani, K Tanaka, H Hyodo, K Oda, A Kimura.   

Abstract

We report a patient with aplastic anemia (AA)-paroxysmal nocturnal hemoglobinuria (PNH) syndrome who developed acute myelogenous leukemia (AML). Flow cytometric analysis showed that the leukemic cells in the bone marrow lacked CD59 antigen on their surface and were positive for P-glycoprotein. Heteroduplex and single-strand conformation polymorphism analysis followed by sequencing of the leukemic cells in the bone marrow disclosed 1 frameshift-type mutation in exon 2 of the phosphatidylinositol glycan-class A (PIG-A) gene, which deductively produces truncated PIG-A protein. These findings provide direct evidence that the leukemic cells evolved from the affected PNH clone. Cytogenetic analysis in the bone marrow in each stage of AA-PNH, AML, and at relapse of AML showed normal, -7, and -7 plus -20, respectively, showing evidence of a clonal evolution. Because complete remission of AML was not achieved by intensive chemotherapies, allogeneic peripheral blood stem cell transplantation (PBSCT) from the patient's HLA-matched sister was performed successfully with recovery of CD59 antigen on bone marrow hematopoietic cells; however, leukemia relapsed 4 months after PBSCT. Leukemia derived from PNH may be resistant to intensive chemotherapy, and a highly myeloablative regimen may be required for stem cell transplantation to eradicate the PNH-derived leukemia clone.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11372733     DOI: 10.1007/bf02981939

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  26 in total

1.  Aggressive natural killer cell leukaemia/lymphoma: report of four cases and review of the literature. Possible existence of a new clinical entity originating from the third lineage of lymphoid cells.

Authors:  N Imamura; Y Kusunoki; K Kawa-Ha; K Yumura; J Hara; K Oda; K Abe; H Dohy; T Inada; H Kajihara
Journal:  Br J Haematol       Date:  1990-05       Impact factor: 6.998

2.  N-RAS gene mutation in patients with aplastic anemia and aplastic anemia/ paroxysmal nocturnal hemoglobinuria during evolution to clonal disease.

Authors:  Y Mortazavi; J A Tooze; E C Gordon-Smith; T R Rutherford
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

3.  Analysis of peroxidase-negative acute unclassifiable leukemias by monoclonal antibodies. 1. Acute myelogenous leukemia and acute myelomonocytic leukemia.

Authors:  N Imamura; R Tanaka; H Kajihara; A Kuramoto
Journal:  Eur J Haematol       Date:  1988-11       Impact factor: 2.997

Review 4.  Paroxysmal nocturnal hemoglobinuria: An acquired genetic disease.

Authors:  J Nishimura; Y Murakami; T Kinoshita
Journal:  Am J Hematol       Date:  1999-11       Impact factor: 10.047

5.  CD59-deficient blood cells and PIG-A gene abnormalities in Japanese patients with aplastic anaemia.

Authors:  Y Azenishi; E Ueda; T Machii; J Nishimura; T Hirota; M Shibano; S Nakao; T Kinoshita; H Mizoguchi; T Kitani
Journal:  Br J Haematol       Date:  1999-03       Impact factor: 6.998

Review 6.  Leukemia arising out of paroxysmal nocturnal hemoglobinuria.

Authors:  J W Harris; R Koscick; H M Lazarus; J R Eshleman; M E Medof
Journal:  Leuk Lymphoma       Date:  1999-02

7.  Long-term survival after marrow transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia.

Authors:  J Szer; H J Deeg; R P Witherspoon; A Fefer; C D Buckner; E D Thomas; R Storb
Journal:  Ann Intern Med       Date:  1984-08       Impact factor: 25.391

8.  Discordant and heterogeneous expression of GPI-anchored membrane proteins on leukemic cells in a patient with paroxysmal nocturnal hemoglobinuria.

Authors:  T Shichishima; T Terasawa; C Hashimoto; H Ohto; M Takahashi; A Shibata; Y Maruyama
Journal:  Blood       Date:  1993-04-01       Impact factor: 22.113

9.  Paroxysmal nocturnal hemoglobinuria with myelofibrosis: progression to acute myeloblastic leukemia.

Authors:  J Nakahata; M Takahashi; I Fuse; Y Nakamori; N Nomoto; H Saitoh; W Tatewaki; A Imanari; T Takeshige; T Koike
Journal:  Leuk Lymphoma       Date:  1993-12

10.  Myelodysplasia following aplastic anaemia-paroxysmal nocturnal haemoglobinuria syndrome after treatment with immunosuppression and G-CSF: evidence for the emergence of a separate clone.

Authors:  J Y Jin; J A Tooze; J C Marsh; F Matthey; E C Gordon-Smith
Journal:  Br J Haematol       Date:  1996-09       Impact factor: 6.998

View more
  7 in total

1.  Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia.

Authors:  Maiko Abumiya; Akiko Mita; Saori Takahashi; Tomoko Yoshioka; Yoshihiro Kameoka; Naoto Takahashi; Masatomo Miura
Journal:  Med Oncol       Date:  2018-05-07       Impact factor: 3.064

2.  Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.

Authors:  Lova Sun; Daria V Babushok
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

3.  Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer.

Authors:  Hayato Yokota; Kazuhiro Sato; Sho Sakamoto; Yuji Okuda; Natsuki Fukuda; Mariko Asano; Masahide Takeda; Katsutoshi Nakayama; Masatomo Miura
Journal:  Invest New Drugs       Date:  2022-09-23       Impact factor: 3.651

Review 4.  Glycosylation in cancer: mechanisms and clinical implications.

Authors:  Salomé S Pinho; Celso A Reis
Journal:  Nat Rev Cancer       Date:  2015-08-20       Impact factor: 60.716

5.  Chronic myeloid leukemia transformation in a patient with paroxysmal nocturnal hemoglobinuria: a rare case report with literature review.

Authors:  Yue Chen; Shandong Tao; Yuan Deng; Lixiao Song; Liang Yu
Journal:  Int J Clin Exp Med       Date:  2015-05-15

6.  Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer.

Authors:  Tomoko Ozeki; Mitsuji Nagahama; Kazuma Fujita; Akifumi Suzuki; Kiminori Sugino; Koichi Ito; Masatomo Miura
Journal:  Sci Rep       Date:  2019-04-01       Impact factor: 4.379

7.  Effects of NR1I2 and ABCB1 Genetic Polymorphisms on Everolimus Pharmacokinetics in Japanese Renal Transplant Patients.

Authors:  Hironobu Yagishita; Hideaki Kagaya; Mitsuru Saito; Kazuyuki Numakura; Ryohei Yamamoto; Ryuichiro Sagehashi; Tomonori Habuchi; Shigeru Satoh; Masatomo Miura
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.